罗欣药业
(002793)
| 流通市值：54.51亿 | | | 总市值：54.60亿 |
| 流通股本：10.86亿 | | | 总股本：10.88亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,077,242,157.53 | 482,726,551.82 | 2,647,365,106.26 | 1,880,916,973.62 |
| 营业收入 | 1,077,242,157.53 | 482,726,551.82 | 2,647,365,106.26 | 1,880,916,973.62 |
| 二、营业总成本 | 1,097,809,739.94 | 510,263,351.88 | 3,114,983,820.66 | 2,162,836,623.58 |
| 营业成本 | 536,921,389.62 | 259,732,186.01 | 1,531,648,273.22 | 1,075,790,076.81 |
| 税金及附加 | 14,147,765.55 | 4,878,626.37 | 20,873,609.97 | 13,777,183.05 |
| 销售费用 | 360,638,263.37 | 152,633,062.39 | 1,141,307,766.76 | 766,646,346.9 |
| 管理费用 | 116,680,886.5 | 57,740,779.84 | 276,439,574.47 | 213,643,590.05 |
| 研发费用 | 37,854,834.9 | 17,179,625.28 | 87,410,791.52 | 49,206,243.34 |
| 财务费用 | 31,566,600 | 18,099,071.99 | 57,303,804.72 | 43,773,183.43 |
| 其中:利息费用 | 28,464,659.34 | 15,694,446.24 | 64,376,783.79 | 47,209,590.88 |
| 其中:利息收入 | 1,132,038.08 | 389,343.32 | 6,297,380.19 | 3,020,325.74 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | - | -213,130,913.8 | - |
| 加:投资收益 | 857,350.34 | -3,406,969.42 | -3,453,844.64 | -12,337,516.69 |
| 资产处置收益 | 4,276,148.66 | -51,243.59 | 240,869.31 | -114,116.34 |
| 资产减值损失(新) | -9,722,180.37 | -2,483,406.13 | -300,719,335.49 | -34,795,918.09 |
| 信用减值损失(新) | 52,777,642.16 | 41,199,257.46 | -14,115,337.87 | 2,237,717.21 |
| 其他收益 | 11,784,971.68 | 8,070,530.74 | 40,297,574.74 | 28,369,555.09 |
| 四、营业利润 | 39,406,350.06 | 15,791,369 | -958,499,702.15 | -298,559,928.78 |
| 加:营业外收入 | 1,022,246.17 | 275,374.7 | 13,074,649.51 | 9,864,415.9 |
| 减:营业外支出 | 2,385,510.78 | 88,856.01 | 7,429,828.96 | 2,638,127.65 |
| 五、利润总额 | 38,043,085.45 | 15,977,887.69 | -952,854,881.6 | -291,333,640.53 |
| 减:所得税费用 | 16,046,303.45 | 13,830,980.74 | 99,403,749.29 | 26,267,578.04 |
| 六、净利润 | 21,996,782 | 2,146,906.95 | -1,052,258,630.89 | -317,601,218.57 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 16,293,842.39 | 2,146,906.95 | -1,052,258,630.89 | -315,549,859.81 |
| 终止经营净利润 | 5,702,939.61 | - | - | -2,051,358.76 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 17,695,049.44 | 5,651,149.5 | -965,496,163.51 | -265,370,489.03 |
| 少数股东损益 | 4,301,732.56 | -3,504,242.55 | -86,762,467.38 | -52,230,729.54 |
| 扣除非经常损益后的净利润 | 2,300,667.52 | 668,954.93 | -768,120,788.93 | -284,454,962.92 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.02 | 0.01 | -0.91 | -0.25 |
| (二)稀释每股收益 | 0.02 | 0.01 | -0.9 | -0.25 |
| 八、其他综合收益 | -154,869.4 | -53,800.09 | 676,112.21 | 212,667.54 |
| 归属于母公司股东的其他综合收益 | -154,334.73 | -53,614.35 | 673,778 | 211,933.33 |
| 九、综合收益总额 | 21,841,912.6 | 2,093,106.86 | -1,051,582,518.68 | -317,388,551.03 |
| 归属于母公司股东的综合收益总额 | 17,540,714.71 | 5,597,535.15 | -964,822,385.51 | -265,158,555.7 |
| 归属于少数股东的综合收益总额 | 4,301,197.89 | -3,504,428.29 | -86,760,133.17 | -52,229,995.33 |
| 公告日期 | 2025-08-28 | 2025-04-22 | 2025-04-22 | 2024-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |